MedTrace Logo

Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases

NCT04967417 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-05-09

Study results available
· View outcomes & findings →

Summary

This is a Phase II single center, open-label, single arm study in patients with advanced non-small cell lung cancer (stage IV) with brain metastases.

This study will be treated with combination of Pembrolizumab 200mg plus platinum doublet based on histology subtypes.

Conditions

Interventions

DRUG

Pemetrexed, Carboplatin, Pembrolizumab

* Pemetrexed 500mg/m2 * Carboplatin AUC 5.0 * Pembrolizumab 200mg

DRUG

Paclitaxel, Carboplatin, Pembrolizumab

* Paclitaxel 200mg/m2 * Caboplatin AUC 6.0 * Pembrolizumab 200mg

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Myung-Ju Ahn, MD, phD · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2024-06-30
Completion
2024-12-02

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04967417 on ClinicalTrials.gov